SensoGenic

Company Overview

Snapshot

Founded in January 2018 by Oded Shoseyov and Alon Yasovsky, SensoGenic operates with 1–10 employees. The company has raised $776.6K across two funding rounds from eHealth Ventures. In April 2019, SensoGenic secured a grant from EU Horizon 2020.

Business overview

SensoGenic is developing a consumer biosensor that leverages its patented molecule-allergen interaction and electronic detection technology. The company aims to provide a comprehensive solution for individuals managing food allergies. Operating within the Health Tech & Life Sciences sector, specifically Digital Healthcare and Digital Therapeutics, SensoGenic serves the global market, targeting patients with its detection technology.

Strategic signal

In June 2022, SensoGenic ceased operations, indicating a significant shift in its market trajectory. This cessation signals to investors and innovation teams that the company's biosensor technology for allergen detection is no longer actively being developed or commercialized, marking a critical inflection point in its journey.

Company Intelligence Q&A

What is SensoGenic's primary focus?

SensoGenic focuses on developing a consumer biosensor based on patented molecule-allergen interaction and electronic detection technology to provide a comprehensive solution for people suffering from food allergies.

When was SensoGenic founded and by whom?

SensoGenic was founded in January 2018 by Oded Shoseyov and Alon Yasovsky.

What was a key funding event for SensoGenic?

In March 2018, SensoGenic received seed funding from eHealth Ventures, which was the sole disclosed investor in this round.

Has SensoGenic received any grants?

Yes, in April 2019, SensoGenic secured a grant from EU Horizon 2020.

What is the current operational status of SensoGenic?

SensoGenic ceased to operate in June 2022.